Immuno-Biological Laboratories Co., Ltd. Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd.

4570

Rank in Stocks #22276
Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to... Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quantitative measurement of targeted substances, alongside comprehensive research support services focusing on areas such as Alzheimer's disease, metabolic syndrome, and cancer. IBL also caters to specific client needs through customized services for antibody production and the development of bespoke ELISA systems. A prominent service is LipoSEARCH, which provides tailored lipoprotein profiling and analysis utilizing gel-filtration high-performance liquid chromatography. This advanced method allows for the in-depth examination of even minute plasma or serum samples from both humans and small animals, supporting a broad spectrum of research, including lipid metabolism, the creation of pharmaceuticals for lifestyle-related diseases, functional food development, and clinical investigations. For animal health, IBL offers LipoTEST, a diagnostic and health screening tool for veterinary clinics, complemented by personalized biomarker testing services for lifestyle-related conditions. Furthermore, the company operates an innovative protein production division that leverages transgenic silkworms. This technology is instrumental in manufacturing antibodies for research and diagnostic applications, human collagen for cosmetic use, proteins for drug development, and other specialized proteins. Established in 1982, Immuno-Biological Laboratories Co., Ltd. is headquartered in Fujioka, Japan.
Share Price
$5.71
Last synced: 2026-11-19
Market Cap
$53.17M
Change (1 day)
2.57%
Change (1 year)
-37.40%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Immuno-Biological Laboratories Co., Ltd. (4570)

Category

Healthcare
Operating Margin for Immuno-Biological Laboratories Co., Ltd. (4570)
Operating Margin as of November 2026 TTM: 31.09%
According to Immuno-Biological Laboratories Co., Ltd.'s latest financial reports, its current operating margin (TTM) is 31.09%. At the end of 2025 the company had an operating margin of 21.59%.
Operating Margin history for Immuno-Biological Laboratories Co., Ltd. from 2020 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 31.09% 44.00%
2025 21.59% 69.07%
2024 12.77% 73.74%
2023 7.35% -138.95%
2022 -18.87% -52.80%
2021 -39.98% -61.36%
2020 -103.47% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -106.28%
US
33.87% -98.91%
US
-116.04% -103.73%
US
25.57% -99.18%
AU
31.23% -99.00%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Immuno-Biological Laboratories Co., Ltd.'s operating margin

What is Immuno-Biological Laboratories Co., Ltd.'s operating margin?

Immuno-Biological Laboratories Co., Ltd.'s operating margin is 31.09%, as of Nov 2026.

What was Immuno-Biological Laboratories Co., Ltd.'s operating margin in 2025?

In 2025, Immuno-Biological Laboratories Co., Ltd.'s operating margin was 21.59%, compared with 12.77% in 2024.

How has Immuno-Biological Laboratories Co., Ltd.'s operating margin changed since 2020?

From 2020 to 2025, Immuno-Biological Laboratories Co., Ltd.'s operating margin was highest in 2025 (21.59%) and lowest in 2020 (-103.47%).

How does Immuno-Biological Laboratories Co., Ltd.'s operating margin compare with similar companies?

Immuno-Biological Laboratories Co., Ltd.'s operating margin (31.09%) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.